Last updated on November 2017

Research Study of ATG and Rituximab in Renal Transplantation (RESTARRT)


Brief description of study

Research Study of ATG and Rituximab in Renal Transplantation (RESTARRT)

Detailed Study Description

RESTARRT is a clinical research study that is testing whether a combination of several medications can reset the immune system and help it accept a new kidney without the need for life-long immunosuppression.

The medications used in RESTARRT are anti-thymocyte globulin (ATG), rituximab, mycophenolate mofetil (MMF), tacrolimus and sirolimus. Participants in the RESTARRT study will receive these medications before, during, and after transplant. Standard immunosuppression drugs will initially be prescribed. Eligible participants will be asked to undergo a gradual reduction of their immunosuppressive medication with the goal of stopping these drugs permanently..

Clinical Study Identifier: TX5496

Contact Investigators or Research Sites near you

Start Over

Joan McElroy, RN, MSN

University of California, San Francisco
San Francisco, CA USA

Onumara Opara

University of Maryland School of Medicine
Baltimore, MD USA

Kerry Crisalli RN, BSN

Massachussetts General Hospital
Boston, MA USA

Tina Gonsalves

The Rogosin Institute - New York Presbyterian
New York, NY USA

Tina Gonsalves

The Rogosin Institute - New York Presbyterian
New York, NY USA

Jennifer Trofe-Clark. Pharm D., BCPS

University of Pennsylvania
Philadelphia, PA USA